Atlas Trials

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

Clinical trial NCT04462328 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04462328
Sponsor
Washington University School of Medicine
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Primary Central Nervous System Lymphoma
Start date
2021-04-29
Primary completion
2026-08-31
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.